TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11443622

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with cisplatin (60 mg/m(2) on Days 1 and 22) and etoposide (100 mg/m(2) on Days 1, 2, 3, 22, 23, 24) plus 5940 cGy radiation in 180-cGy fractions over 6 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with surgical resection
Number of subjects: 42
Study: 9514312

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8064994

Group type: EXPERIMENTAL
Intervention: Hypocaloric (HC) feeding (50% resting metabolic energy expenditure, plus protein; calories:nitrogen = 75:1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C) feeding (100% resting metabolic energy expenditure, plus protein; calories:nitrogen = 150:1)
Number of subjects: 16
Study: 31498370

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 52
Study: 31342445

Group type: EXPERIMENTAL
Intervention: Pathways Early ASD Intervention (n=32)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) (n=24)
Number of subjects: 56
Study: 28835597

Group type: EXPERIMENTAL
Intervention: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste applied twice a day for 36 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fluoridated toothpaste applied twice a day for 36 months
Number of subjects: 41
Study: 26563906

Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention consisting of three one-hour low-intensity outdoor running sessions a week
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wait list (control)
Number of subjects: 108
Study: 23288297

Group type: EXPERIMENTAL
Intervention: Guideline-based care
Number of subjects: 523

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 523
Study: 20096957

Group type: EXPERIMENTAL
Intervention: CBP gene variants (intron 4CT and intron 3AC polymorphisms)
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Haplotype with variant alleles of intron 4CT and intron 3AC polymorphisms
Number of subjects: 5804
Study: 18393298

Group type: EXPERIMENTAL
Intervention: Single dose of lofexidine hydrochloride (1.2 mg and 2.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidose of lofexidine hydrochloride (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of lofexidine hydrochloride (1.2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of lofexidine hydrochloride (2.0 mg)
Number of subjects: 0
Study: 16618360

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (GLA) supplementation
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (non-supplemented group)
Number of subjects: 131
Study: 15181099

Group type: EXPERIMENTAL
Intervention: Acylated ghrelin (AG) 1.0 microg/kg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin (UAG) alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Co-administration of UAG and AG
Number of subjects: 6
Study: 11107710

Group type: EXPERIMENTAL
Intervention: Ciclopirox 8% nail lacquer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclopirox 8% nail lacquer (meta-analysis)
Number of subjects: 0
Study: 9288642

Group type: EXPERIMENTAL
Intervention: Improved stereological technique for estimating volumes of structures in three-dimensional arrays
Number of subjects: 0
Study: 8347054

Group type: EXPERIMENTAL
Intervention: Carbamazepine 600 mg/day
Number of subjects: 14
Study: 3538486

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 100 micrograms four times daily
Number of subjects: 31
Study: 29716611

Group type: EXPERIMENTAL
Intervention: Video assisted learning plus a nodal point operation primer (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Video assisted learning (Group A)
Number of subjects: 45
Study: 26927662

Group type: EXPERIMENTAL
Intervention: CIMAvax-EGF vaccine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: CIMAvax-EGF vaccine (per-protocol setting)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Best supportive care (per-protocol setting)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: CIMAvax-EGF vaccine (high EGF concentration at baseline)
Number of subjects: 405
Study: 24360369

Group type: EXPERIMENTAL
Intervention: Tafenoquine 50 mg plus chloroquine
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg plus chloroquine
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg plus chloroquine
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Tafenoquine 600 mg plus chloroquine
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Primaquine 15 mg for 14 days plus chloroquine
Number of subjects: 329

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 329

Group type: COMPARATOR
Intervention: Tafenoquine 300 mg vs Chloroquine alone
Number of subjects: 329

Group type: COMPARATOR
Intervention: Tafenoquine 600 mg vs Chloroquine alone
Number of subjects: 329

Group type: COMPARATOR
Intervention: Primaquine vs Chloroquine alone
Number of subjects: 329
Study: 22665535

Group type: EXPERIMENTAL
Intervention: Carboplatin and vincristine (CV)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Thioguanine, procarbazine, lomustine, and vincristine (TPCV)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Both regimens (CV and TPCV)
Number of subjects: 274
Study: 21121823

Group type: EXPERIMENTAL
Intervention: Researcher access to eligible participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organisational culture and attitudes of service providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of collaborative partnerships between research and clinical communities
Number of subjects: 0
Study: 18696358

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g)
Number of subjects: 708
Study: 16038370

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 59
Study: 12061359

Group type: EXPERIMENTAL
Intervention: Continuous gastric drip (CGD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravenous (i.v.) fluids
Number of subjects: 58
Study: 10051076

Group type: EXPERIMENTAL
Intervention: High PEEP (15 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inverse I:E ratio (2:1) with low PEEP (5 cm H2O)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low PEEP (5 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High PEEP or IRV
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: A‐aDO2 and PaO2/PAO2
Number of subjects: 23
Study: 7473116

Group type: EXPERIMENTAL
Intervention: Anterior chamber fluid from phacoemulsification surgery
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sterile balanced salt solution (control)
Number of subjects: 103
Study: 1693033

Group type: EXPERIMENTAL
Intervention: Environment-sensitive episodes in unipolar depressed patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomous episodes in bipolar depressed patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environment-sensitive episodes in bipolar depressed patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environment-sensitive episodes in manic subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomous episodes in manic subjects
Number of subjects: 0
Study: 7004214

Group type: EXPERIMENTAL
Intervention: Mefloquine hydrochloride (WR 142,490)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine
Number of subjects: 0
Study: 29275638

Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 28364461

Group type: EXPERIMENTAL
Intervention: Armodafinil (150-250 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27053145

Group type: EXPERIMENTAL
Intervention: Optimal pressure ulcer-preventative care group (treatment) - regular turning every 2 hours with at least 15 minutes of tissue decompression.
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Standard care group (control) - no specific intervention details provided.
Number of subjects: 1812
Study: 25124510

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) added to psychopharmacological treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief structured group psychoeducational intervention added to psychopharmacological treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical management including psychopharmacological treatment
Number of subjects: 0
Study: 21479698

Group type: EXPERIMENTAL
Intervention: KIR2DS1
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2DS4 (2DS4 003/4/6/7)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2DL1
Number of subjects: 110
Study: 19166627

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions implemented in 5630 individuals
Number of subjects: 15005

Group type: COMPARATOR
Intervention: Control group of 9375 individuals
Number of subjects: 15005
Study: 17244451

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 1.0 mg once daily for 168 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16279289

Group type: EXPERIMENTAL
Intervention: Open trial design (no placebo)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Blinded, placebo-controlled design
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Open trial design
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Open trial no tablet group
Number of subjects: 180
Study: 11673219

Group type: EXPERIMENTAL
Intervention: Ozone (O3) exposure (0.25 ppm x 2 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 8
Study: 9412558

Group type: EXPERIMENTAL
Intervention: 0.15 IU/kg rhGH daily for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8430402

Group type: EXPERIMENTAL
Intervention: Peer-led education
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Teacher-led education
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15
Study: 3113223

Group type: EXPERIMENTAL
Intervention: Continuous nitroglycerin patch therapy for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-hour-daily intermittent nitroglycerin patch therapy for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study: 29847426

Group type: EXPERIMENTAL
Intervention: Intraarticular facet injections with bupivacaine and steroid
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Medial branch blocks
Number of subjects: 229

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 229
Study: 26200198

Group type: EXPERIMENTAL
Intervention: Eccentric training program (6-week duration, specific to swing phase, high-load open-chain kinetic movements)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (usual track and field training, no additional eccentric exercises)
Number of subjects: 20
Study: 23474641

Group type: EXPERIMENTAL
Intervention: Childhood sexual and physical abuse
Number of subjects: 0
Study: 22492369

Group type: EXPERIMENTAL
Intervention: PUFA diet (high in vegetable n-6 PUFA)
Number of subjects: 67
Study: 20357374

Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study: 18076538

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 23
Study: 16214493

Group type: EXPERIMENTAL
Intervention: Contraction times measured at stimulus intensity 10% of supramaximal stimulus (10% MS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Percentage of type 1 muscle fibers measured at the surface of the muscle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Percentage of type 1 muscle fibers measured in the deep region of the muscle
Number of subjects: 30
Study: 11943558

Group type: EXPERIMENTAL
Intervention: Hormone-guided therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 69
Study: 10634050

Group type: EXPERIMENTAL
Intervention: Mixture of bupivacaine, mepivacaine and hyaluronidase (sub-group M)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Bupivacaine alone (sub-group B)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Retrobulbar blockade
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Peribulbar blockade
Number of subjects: 399
Study: 7536861

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: GC-MS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunoassays (TDx, EMIT, ABUS, CAC)
Number of subjects: 0
Study: 1974402

Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 30
Study: 6797132

Group type: EXPERIMENTAL
Intervention: Amino acid‐carbohydrate‐electrolyte infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Carbohydrate‐electrolyte infusion
Number of subjects: 22
Study: 31539599

Group type: EXPERIMENTAL
Intervention: Engage (Coping Skills Training and Acceptance and Commitment Therapy)
Number of subjects: 24
Study: 30673062

Group type: EXPERIMENTAL
Intervention: IYP program plus HPS
Number of subjects: 126

Group type: COMPARATOR
Intervention: IYP program alone
Number of subjects: 126
Study: 28204740

Group type: EXPERIMENTAL
Intervention: Early intervention by a physical therapist (n = 84)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care by primary care provider (n = 97)
Number of subjects: 181
Study: 25549933

Group type: EXPERIMENTAL
Intervention: Acupuncture (100% post-treatment expectations)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Acupuncture (0% post-treatment expectations)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Acupuncture (100% baseline expectations)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Acupuncture (0% baseline expectations)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 476
Study: 24220287

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) alone
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) + Mefloquine (MQ)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX)
Number of subjects: 432
Study: 20923463

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycerol ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 19465858

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional, nonbiologic pharmacotherapy
Number of subjects: 0
Study: 17264176

Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/d
Number of subjects: 50
Study: 15374727

Group type: EXPERIMENTAL
Intervention: Sequential transdermal estrogen‐progestin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic acid supplementation for 6 months
Number of subjects: 0
Study: 11466135

Group type: EXPERIMENTAL
Intervention: Prolonged QTc dispersion (> or = 70 msec)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Increased QTc dispersion and left ventricular hypertrophy on ECG
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: QTcmin (the shortest QTc interval among the 12 leads of ECG)
Number of subjects: 330
Study: 9736231

Group type: EXPERIMENTAL
Intervention: Individual training by a nurse (Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Home training after individual instruction (Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Placebo Turbuhaler and practice at home (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No individual training (Group B)
Number of subjects: 72
Study: 8295841

Group type: EXPERIMENTAL
Intervention: Child behavioral information
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Parental role information
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of child behavioral and parental role information
Number of subjects: 108
Study: 3987783

Group type: EXPERIMENTAL
Intervention: Nadolol alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nadolol plus indapamide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nadolol plus xipamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Previous three drug regimens (beta blocker and two other antihypertensive agents)
Number of subjects: 24
Study: 31908251

Group type: EXPERIMENTAL
Intervention: Preoperative focused cardiac ultrasound (FOCUS)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no preoperative FOCUS)
Number of subjects: 800
Study: 28910848

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 µg)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 27107394

Group type: EXPERIMENTAL
Intervention: Iron tablet (ferrous sulfate, 200 mg)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Iron infusion
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Dietary controls
Number of subjects: 1011
Study: 24618837

Group type: EXPERIMENTAL
Intervention: PCV-7
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PCV-13
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PCV-13 booster
Number of subjects: 108
Study: 22766415

Group type: EXPERIMENTAL
Intervention: Modified prolonged exposure intervention (3 sessions, initiated in the emergency department)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Assessment only control group
Number of subjects: 137
Study: 20413516

Group type: EXPERIMENTAL
Intervention: Benfotiamine (900 mg/day) for 12 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 18624629

Group type: EXPERIMENTAL
Intervention: Having at least 3 medical care visits in a 6-month period
Number of subjects: 316

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 316
Study: 17047160

Group type: COMPARATOR
Intervention: Insulin clamp at 5 mU x m(-2) x min(-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insulin clamp at 30 mU x m(-2) x min(-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin clamp at 55 mU x m(-2) x min(-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin clamp at 105 mU x m(-2) x min(-1)
Number of subjects: 8
Study: 15081627

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 34
Study: 10908888

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a) 30 mcg IM once weekly
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 8956922

Group type: EXPERIMENTAL
Intervention: Intracarotid amobarbital procedure (IAP) with 125 mg sodium amytal injection
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Total Memory Score
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dominant hemisphere performance
Number of subjects: 56
Study: 1372470

Group type: EXPERIMENTAL
Intervention: Topical 5‐fluorouracil
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Laser alone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Systemic interferon
Number of subjects: 71

Group type: COMPARATOR
Intervention: Combined 5‐fluorouracil and laser
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Crossover to interferon regimen (1 or 3 MIU)
Number of subjects: 71
Study: 3937154

Group type: EXPERIMENTAL
Intervention: Single patient education strategy (clinic exit interview)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double patient education strategy (clinic exit interview + educational meeting with family)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple patient education strategy (clinic exit interview + educational meeting with family + small group sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 0
Study: 31320446

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 1 mg, 2 mg, 3 mg, 4 mg once weekly
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Efpeglenatide ≥1 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 3 mg, 4 mg once weekly
Number of subjects: 254

Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 28705551

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (PDC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 30
Study: 27903250

Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft with PAOO
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bioactive glass with PAOO
Number of subjects: 33

Group type: COMPARATOR
Intervention: Modified corticotomy (Control group)
Number of subjects: 33
Study: 24678813

Group type: EXPERIMENTAL
Intervention: Goserelin, 2 monthly doses (n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Goserelin, 3 monthly doses (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group, no treatment (n = 32)
Number of subjects: 36
Study: 22041453

Group type: EXPERIMENTAL
Intervention: Maternal or infant antiretroviral interventions offered after DSMB recommendation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Enhanced standard-of-care (control) arm
Number of subjects: 67
Study: 20359401

Group type: EXPERIMENTAL
Intervention: EHR-integrated, documentation-based clinical decision support system (ARI Smart Form)
Number of subjects: 21961

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21961